If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

No evidence or no alternative? Taking responsibility for off‐label prescribing

$48.00 plus tax (Refund Policy)

Download / Buy Article:

Abstract:

Abstract

Recombinant activated factor VII (rFVIIa) is registered for patients with rare haematological disorders, but is used ‘off‐label’ in many other situations, including intracranial haemorrhage, cardiac surgery, trauma, transplantation and prostatectomy. Lack of systematic evidence to support these off‐label uses has not slowed the growth of off‐label prescribing of rFVIIa. We use the case of rFVIIa to illustrate the issues raised by off‐label prescribing, and the kind of impasse that can arise when views about evidence, expertise and clinical necessity are in conflict. We argue that clinicians, hospital drug committees and regulators all need to acknowledge the complexity of prescribing decisions, and ensure that decisions to prescribe off‐label are sufficiently justified.

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1445-5994.2012.02713.x

Affiliations: Australian Institute of Health Innovation

Publication date: March 1, 2012

Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more